Compare ADMA Biologics Inc (ADMA) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Linde PLC — how do they compare? ADMA Biologics Inc trades at $9.21 (market cap $2.13B), while Linde PLC trades at $530.21 (market cap $248.85B). The key difference: Linde PLC is far larger — about 116.8× ADMA Biologics Inc's market cap, and Linde PLC pays a 1.19% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LIN | |
|---|---|---|
Market Cap | $2.13B | $248.85B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $546.64 |
52-Week Low | $7.60 | $389.38 |
Enterprise Value | $2.20B | $271.21B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Linde (LIN) trades at $540.52, down 1.12% on the day, with a bullish technical outlook supported by moving averages and key resistance at $546. The company reported strong Q1 2026 EPS of $4.33, beating estimates, and maintains robust profitability with a 20.44% net income margin. Recent news highlights sustainability leadership and strategic growth, while cash flow remains positive despite projected 2026 outflows.
Outlook remains positive with 85.7% analyst buy ratings and a $570.80 consensus price target, suggesting 5.6% upside. Risks include rising debt-to-asset ratio (31.63% in 2025) and valuation concerns (P/E 35.84). The stock offers a dividend yield of approximately 0.3% with consistent shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
